HAVCR2 and diffuse large B-cell lymphoma: The enrichment of TIM-3/Galectin-9 is related to an immunosuppressive TME, severe clinical manifestations, inferior prognosis, and poor RTT with CHOP and can predict the clinical efficacy of immune checkpoint blockade therapy in DLBCL [537].